Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon vaccines, delivered using the company's proprietary electroporation technology, are generating best-in-class immune responses, with therapeutic T cells exceeding other technologies. Inovio's lead vaccine, a therapeutic against HPV-caused precancers and cancers, is in phase 2. Other phase 1 and preclinical programs target prostate, breast and lung cancers as well as HIV, influenza, malaria and hepatitis. Roche and Inovio have an exclusive worldwide partnership to develop and commercialize Inovio's DNA immunotherapies for prostate cancer and hepatitis B.

Expert Comments:

Yi Chen, H.C. Wainwright & Co. (7/24/15)
"Inovio Pharmaceuticals Inc. announced yesterday that the company has a collaboration with the European Organization for Research and Treatment of Cancer (EORTC) to evaluate the company's INO-3112 immunotherapy in combination of traditional chemo-radiotherapy in a Phase 2 trial to treat locally advanced stage cervical cancer. This trial is primarily funded by the EORTC and is expected to begin by the end of 2015. . .in the wake of this update, we reiterate our Buy rating and $17/share price target."

Jason Kolbert, Maxim Group (7/23/15)
"Inovio Pharmaceuticals Inc. announced that the company will collaborate with the European Organization for Research and Treatment of Cancer (EORTC) to evaluate INO-3112 (VGX-3100 + IL-12-based immune activator) in a large Phase 2 study in women with advanced-stage cervical cancer. The EORTC, the largest cancer research organization in Europe. . .coming on board further validates Inovio's cancer immunotherapy platform. Inovio is continuing to make progress in multiple indications spanning oncology and infectious disease. We also expect more big pharma partners to be attracted to the platform."

Jason McCarthy, Maxim Group (7/2/15)
"Inovio Pharmaceuticals Inc.'s lead product is VGX-3100, which targets human papilloma virus-related cervical dysplasia, the precursor to cervical cancer. . .a Phase 3 pivotal study is in the final planning stages and should initiate in late 2015."

"Invoio Pharmaceuticals Inc. has a broad platform that includes an IL-12 DNA vaccine, but also several other DNA vaccines for both cancer and infectious diseases. These include DNA vaccines designed to produce specific tumor antigens or immune activators, such as IL-12, as well as functional monoclonal antibodies targeting certain viral antigens. Last year, the company reported positive results from a Phase 2 trial of its vaccine, called VGX-3100, targeting certain human papillomavirus (HPV) antigens in patients with high-grade cervical intraepithelial neoplasia (cervical dysplasia) caused by HPV types 16 or 18. The study showed that VGX-3100 induced a robust T-cell response, just what it was designed to do." read more >

Bret Jensen, Seeking Alpha (5/29/15)
"Inovio Pharmaceuticals Inc. is a promising vaccine maker with a market capitalization of approximately $600M at current levels. The company has several things to recommend it for aggressive growth investors, including a deep pipeline, solid balance sheet and partnerships with larger players. . .it is a good time to take a look at Inovio, as it just announced it will team up with GeneOne Life Science Inc. to develop a DNA vaccine for Middle East Respiratory Syndrome."

"I understand Inovio Pharmaceuticals Inc. is using active DNA vaccines. Inovio and OncoSec Medical are both seemingly following a similar theme, and the growing acceptance and excitement around immunotherapies in general may help them both. Inovio has had a number of successes clinically and marquee collaborations that have led to its market cap being what it is today. Thus, it has a market cap of about $590M today, versus OncoSec's $57M." read more >

More Expert Comments

Experts Commenting on This Company

Yi Chen, Managing Director of Equity Research – H.C. Wainwright & Co.
Charles Duncan, Managing Director, Senior Biotechnology Analyst – Piper Jaffray & Co.
Christopher James, Managing Director, Senior Equity Research Analyst – Brinson Patrick Securities Corporation
Jason Kolbert, Senior Analyst – Maxim Group
Jason Russ, Author Seeking Alpha
Ram Selvaraju, Senior Analyst – MLV & Co
Ross Silver, Co-Founder and Principal Analyst – Vista Partners
Jill Wahleithner, Fund Manager – Wasatch Funds
George Zavoico, Senior Equity Analyst – JonesTrading International Services LLC

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Inovio Pharmaceuticals Inc. Content